When you or someone you love is admitted to a major hospital for a life-saving transplant, the last thing on your mind is the air you're breathing. For at least six patients at Sydney's Royal Prince Alfred Hospital last year, that air may have been the source of a deadly fungal infection.
Sydney Local Health District (SLHD) has confirmed it is investigating a cluster of Aspergillus infections in the hospital's transplant ward, recorded between October and December. Two patients died and four others fell seriously ill, according to 9News. The investigation has raised uncomfortable questions about whether the hospital's $940 million redevelopment, underway since 2023, may have stirred up conditions that put the most vulnerable patients at serious risk.
Aspergillus is a common mould found in soil, dust, and damp environments, particularly around construction and demolition sites. Most healthy people inhale its spores daily without any ill effect. For patients with compromised immune systems, including those recovering from organ transplants, the story is very different. Serious symptoms include breathlessness, coughing up blood, and in the worst cases, respiratory failure.
From a patient safety standpoint, the timing is deeply concerning. Large-scale hospital construction projects are not unusual in Australia's public health system, but they carry well-documented infection risks. The question of whether adequate precautions were in place throughout the redevelopment period, and whether those precautions were sufficient given the proximity of a high-risk transplant unit, is one that health authorities now need to answer clearly and publicly.
SLHD moved to contain the situation once the cluster was identified, closing the affected ward, relocating transplant patients, and contacting those potentially at risk. A panel of experts, including NSW Chief Health Officer Kerry Chant, later cleared the ward for reopening after testing found no elevated levels of the fungus. The district also undertook a deep clean, reviewed air intake points, upgraded filtration systems, and carried out comprehensive air quality testing.
The health district's spokesperson extended condolences to the families of those who died and noted that "fungal infections are a known risk for patients who are significantly immunocompromised, including patients undergoing organ transplant procedures." That context is fair. No hospital can eliminate every risk faced by its most critically ill patients, and transplant recipients face heightened vulnerability to a wide range of pathogens well beyond Aspergillus.
Supporters of the redevelopment project would rightly argue that investing $940 million in Royal Prince Alfred's infrastructure is exactly what keeps the facility operating at the level Australians expect from a world-class hospital. Delaying or under-resourcing such work carries its own costs to patient care over the long term. The genuine challenge lies in managing the construction environment so that activity near high-risk clinical areas does not compromise infection control for those who cannot afford even minor lapses.
What this case reveals is that the systems designed to protect immunocompromised patients during major construction works demand the same rigour as any other aspect of clinical care. The Australian Department of Health and its state counterparts have a responsibility to review whether infection control protocols during hospital redevelopments are fit for purpose, and to publish their findings in full. SLHD has confirmed its investigation is ongoing. The families who have lost loved ones deserve a thorough, independent account of what happened and what will prevent it from happening again.